Kui K. Chan

Kui K. Chan

Auto-generated profile, based on publicly available information

Kui K. Chan

Orthogonal Biologics, Champaign, IL 61821, USA

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 September 2020 in Science
Verified
Journal Article
Open access
PDF file
KCKui K. Chan
Kui K. Chan
DDDanielle Dorosky
Danielle Dorosky
PSPreeti Sharma
Preeti Sharma
SAShawn A. Abbasi
Shawn A. Abbasi
JDJohn Dye
John Dye
EPErik Procko
Erik Procko
A decoy receptor for SARS-CoV-2: For severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to enter human cells, the spike protein on the surface of the virus must bind to the host receptor protein, angiotensin-converting enzyme 2 (ACE2). A soluble version of the receptor is being explored as a therapeutic. Chan et al. used deep mutagenesis to identify ACE2 mutants that bind more tightly to the spike protein and combined mutations to further increase binding affinity (see the Perspective by DeKosky). A promising variant was engineered to be a stable dimer that has a binding affinity for the spike protein; it is comparable with neutralizing antibodies and neutralized both SARS-CoV-2 and SARS-CoV-1 in a cell-based assay. In addition, the similarity to the natural receptor may limit the possibility for viral escape. Science , this issue p. 1261 ; see also p. 1167

19 February 2021 in Science Advances
Verified
Journal Article
Open access
PDF file
KCKui K. Chan
Kui K. Chan
TTTimothy Tan
Timothy Tan
KNKrishna K. Narayanan
Krishna K. Narayanan
EPErik Procko
Erik Procko
The spike S of SARS-CoV-2 recognizes ACE2 on the host cell membrane to initiate entry. Soluble decoy receptors, in which the ACE2 ectodomain is engineered to block S with high affinity, potently neutralize infection and, due to close similarity with the natural receptor, hold out the promise of being broadly active against virus variants without opportunity for escape. Here, we directly test this hypothesis. We find an engineered decoy receptor, sACE22.v2.4, tightly binds S of SARS-associated viruses from humans and bats, despite the ACE2-binding surface being a region of high diversity. Saturation mutagenesis of the receptor-binding domain followed by in vitro selection, with wild type ACE2 and the engineered decoy competing for binding sites, failed to find S mutants that discriminate in favor of the wild type receptor. We conclude that resistance to engineered decoys will be rare and that decoys may be active against future outbreaks of SARS-associated betacoronaviruses.

11 January 2008 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
TATina L. Amyes
Tina L. Amyes
BWBryant M. Wood
Bryant M. Wood
KCKui Chan
Kui Chan
JGJohn A. Gerlt
John A. Gerlt
JRJohn P. Richard
John P. Richard

12 May 2009 in Biochemistry
Verified
Journal Article
Closed access
KCKui K. Chan
Kui K. Chan
BWB. McKay Wood
B. McKay Wood
AFAlexander A. Fedorov
Alexander A. Fedorov
EFElena V. Fedorov
Elena V. Fedorov
HIHeidi J. Imker
Heidi J. Imker
JGJohn A. Gerlt
John A. Gerlt

1 October 2007 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
KTKrisztina Toth
Krisztina Toth
TATina L. Amyes
Tina L. Amyes
BWBryant M. Wood
Bryant M. Wood
KCKui Chan
Kui Chan
JGJohn A. Gerlt
John A. Gerlt
JRJohn P. Richard
John P. Richard

12 May 2009 in Biochemistry
Verified
Journal Article
Closed access
BWB. McKay Wood
B. McKay Wood
KCKui K. Chan
Kui K. Chan
TATina L. Amyes
Tina L. Amyes
JRJohn P. Richard
John P. Richard
JGJohn A. Gerlt
John A. Gerlt